Boston Scientific (BSX) Stock Forecast & Price Target

Compare

3,673 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BSX Analyst Ratings

Strong Buy

23 Buy

1 Hold

0 Sell

Based on 24 analysts giving stock ratings to

Boston

Scientific

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BSX Stock 12 Month Forecast

Average Price Target

$126.05

▲(26.18% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $126.05 with a high forecast of $140.00 and a low forecast of $113.00. The average price target represents a 26.18% change from the last price of $99.90.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"82":"$82","141":"$141","96.75":"$96.8","111.5":"$111.5","126.25":"$126.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":140,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$140.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":126.05,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$126.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":113,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$113.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[82,96.75,111.5,126.25,141],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.85,99.24615384615385,102.64230769230768,106.03846153846153,109.43461538461538,112.83076923076922,116.22692307692307,119.62307692307692,123.01923076923077,126.41538461538461,129.81153846153848,133.2076923076923,136.60384615384615,{"y":140,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.85,98.17307692307692,100.49615384615385,102.81923076923076,105.14230769230768,107.46538461538461,109.78846153846153,112.11153846153846,114.43461538461538,116.75769230769231,119.08076923076922,121.40384615384615,123.72692307692307,{"y":126.05,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,95.85,97.16923076923077,98.48846153846154,99.8076923076923,101.12692307692308,102.44615384615385,103.76538461538462,105.08461538461538,106.40384615384615,107.72307692307692,109.04230769230769,110.36153846153846,111.68076923076923,{"y":113,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":84.14,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.62,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.79,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.19,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.17,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104.78,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.41,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":95.85,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$140.00

Average Price Target$126.05

Lowest Price Target$113.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Josh Jennings

TD Cowen

$115

Buy

15.12%

Upside

Reiterated

10/22/25

Boston Scientific's Strong Financial Performance and Positive Outlook Earns Buy Rating

Vijay Kumar

Evercore ISI

$110→$113

Buy

13.11%

Upside

Reiterated

10/22/25

Boston Scientific's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating

David Roman

Goldman Sachs

$120→$124

Buy

24.12%

Upside

Reiterated

10/22/25

Boston Scientific price target raised to $124 from $120 at Goldman SachsBoston Scientific price target raised to $124 from $120 at Goldman Sachs

Michael Matson

Needham

$121

Buy

21.12%

Upside

Reiterated

10/22/25

Boston Scientific's Strong Q3 Performance and WATCHMAN Growth Justify Buy Rating

Marie Thibault

BTIG

$132

Buy

32.13%

Upside

Reiterated

10/22/25

BTIG Sticks to Their Buy Rating for Boston Scientific (BSX)

Richard Newitter

Truist Financial

―

Buy

―

Reiterated

10/20/25

Boston Scientific (BSX) Receives a Buy from Truist Financial

Mike Kratky

Leerink Partners

―

Buy

―

Reiterated

10/17/25

Boston Scientific gets another winner with Nalu acquisition, says LeerinkBoston Scientific gets another winner with Nalu acquisition, says Leerink

William Plovanic

Canaccord Genuity

$132

Buy

32.13%

Upside

Reiterated

10/17/25

Analysts' Top Healthcare Picks: Evaxion Biotech (EVAX), Bristol-Myers Squibb (BMY)Bottom line: BSX announced via press release this morning, October 17 th , prior to market open, that it has an agreement to acquire Nalu Medical. Nalu Medical is a neuromodulation company with the leading commercial Peripheral Nerve Stimulation (PNS) device to treat chronic neuropathic pain. BSX has agreed to pay ~$533M in upfront cash, which excludes BSX’s existing strategic investments in the company ($600M including). Nalu’s technology will fit into BSX’s Neuromodulation business and will complement the SCS business. PNS should not cannibalize the SCS business, but we note that the Nalu system is cleared for SCS, although it is a small part of Nalu’s business because the company has been primarily focused on spearheading the PNS market.

Shagun Singh Chadha

RBC Capital

―

Buy

―

Reiterated

10/09/25

Travis Steed

Bank of America Securities

$120

Buy

20.12%

Upside

Reiterated

10/08/25

Bank of America Securities Remains a Buy on Boston Scientific (BSX)We maintain our Buy rating on Boston Scientific given its durable growth with best-in-class EPS growth outlook.

Hans Engel

Erste Group

―

Hold

―

Downgraded

10/03/25

Boston Scientific downgraded to Hold from Buy at Erste GroupBoston Scientific downgraded to Hold from Buy at Erste Group

Suraj Kalia

Oppenheimer

$125

Buy

25.13%

Upside

Reiterated

10/01/25

Oppenheimer Sticks to Their Buy Rating for Boston Scientific (BSX)Oppenheimer analyst Suraj Kalia reiterated an Outperform rating and $125.00 price target on Boston Scientific (NYSE: BSX).

Matt Miksic

Barclays

$133→$136

Buy

36.14%

Upside

Reiterated

10/01/25

Barclays Sticks to Its Buy Rating for Boston Scientific (BSX)Barclays analyst Matt Miksic raised the price target on Boston Scientific (NYSE: BSX) to $136.00 (from $133.00) while maintaining a Overweight rating.

David Rescott

Robert W. Baird

$123→$128

Buy

28.13%

Upside

Reiterated

10/01/25

Boston Scientific price target raised to $128 from $123 at BairdBoston Scientific price target raised to $128 from $123 at Baird

Rick Wise

Stifel Nicolaus

$97.63→$125

Buy

25.13%

Upside

Reiterated

10/01/25

Stifel Nicolaus Keeps Their Buy Rating on Boston Scientific (BSX)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Josh Jennings

TD Cowen

$115

Buy

15.12%

Upside

Reiterated

10/22/25

Boston Scientific's Strong Financial Performance and Positive Outlook Earns Buy Rating

Vijay Kumar

Evercore ISI

$110→$113

Buy

13.11%

Upside

Reiterated

10/22/25

Boston Scientific's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating

David Roman

Goldman Sachs

$120→$124

Buy

24.12%

Upside

Reiterated

10/22/25

Boston Scientific price target raised to $124 from $120 at Goldman SachsBoston Scientific price target raised to $124 from $120 at Goldman Sachs

Michael Matson

Needham

$121

Buy

21.12%

Upside

Reiterated

10/22/25

Boston Scientific's Strong Q3 Performance and WATCHMAN Growth Justify Buy Rating

Marie Thibault

BTIG

$132

Buy

32.13%

Upside

Reiterated

10/22/25

BTIG Sticks to Their Buy Rating for Boston Scientific (BSX)

Richard Newitter

Truist Financial

―

Buy

―

Reiterated

10/20/25

Boston Scientific (BSX) Receives a Buy from Truist Financial

Mike Kratky

Leerink Partners

―

Buy

―

Reiterated

10/17/25

Boston Scientific gets another winner with Nalu acquisition, says LeerinkBoston Scientific gets another winner with Nalu acquisition, says Leerink

William Plovanic

Canaccord Genuity

$132

Buy

32.13%

Upside

Reiterated

10/17/25

Shagun Singh Chadha

RBC Capital

―

Buy

―

Reiterated

10/09/25

Travis Steed

Bank of America Securities

$120

Buy

20.12%

Upside

Reiterated

10/08/25

Bank of America Securities Remains a Buy on Boston Scientific (BSX)We maintain our Buy rating on Boston Scientific given its durable growth with best-in-class EPS growth outlook.

Hans Engel

Erste Group

―

Hold

―

Downgraded

10/03/25

Boston Scientific downgraded to Hold from Buy at Erste GroupBoston Scientific downgraded to Hold from Buy at Erste Group

Suraj Kalia

Oppenheimer

$125

Buy

25.13%

Upside

Reiterated

10/01/25

Oppenheimer Sticks to Their Buy Rating for Boston Scientific (BSX)Oppenheimer analyst Suraj Kalia reiterated an Outperform rating and $125.00 price target on Boston Scientific (NYSE: BSX).

Matt Miksic

Barclays

$133→$136

Buy

36.14%

Upside

Reiterated

10/01/25

David Rescott

Robert W. Baird

$123→$128

Buy

28.13%

Upside

Reiterated

10/01/25

Boston Scientific price target raised to $128 from $123 at BairdBoston Scientific price target raised to $128 from $123 at Baird

Rick Wise

Stifel Nicolaus

$97.63→$125

Buy

25.13%

Upside

Reiterated

10/01/25

Stifel Nicolaus Keeps Their Buy Rating on Boston Scientific (BSX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Boston Scientific

1 Month

xxx

Success Rate

22/28 ratings generated profit

Average Return

+2.14%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 78.57% of your transactions generating a profit, with an average return of +2.14% per trade.

3 Months

xxx

Success Rate

18/22 ratings generated profit

Average Return

+6.95%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +6.95% per trade.

1 Year

Richard NewitterTruist Financial

Success Rate

23/25 ratings generated profit

Average Return

+28.87%

reiterated a buy rating 3 days ago

Copying Richard Newitter's trades and holding each position for 1 Year would result in 92.00% of your transactions generating a profit, with an average return of +28.87% per trade.

2 Years

xxx

Success Rate

31/33 ratings generated profit

Average Return

+49.82%

reiterated a xxx

rating 22 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 93.94% of your transactions generating a profit, with an average return of +49.82% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BSX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BSX has received 48 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BSX average Analyst price target in the past 3 months is 126.05.

Each month's total comprises the sum of three months' worth of ratings.

BSX Financial Forecast

BSX Earnings Forecast

Next quarter’s earnings estimate for BSX is $0.78 with a range of $0.76 to $0.79. The previous quarter’s EPS was $0.75. BSX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year BSX has Preformed in-line its overall industry.

BSX Sales Forecast

Next quarter’s sales forecast for BSX is $5.26B with a range of $5.14B to $5.33B. The previous quarter’s sales results were $5.07B. BSX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year BSX has Preformed in-line its overall industry.

BSX Stock Forecast FAQ

What is BSX’s average 12-month price target, according to analysts?

Based on analyst ratings, Boston Scientific’s 12-month average price target is 126.05.

What is BSX’s upside potential, based on the analysts’ average price target?

Boston Scientific has 26.18% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BSX a Buy, Sell or Hold?

Boston Scientific has a consensus rating of Strong Buy which is based on 23 buy ratings, 1 hold ratings and 0 sell ratings.

What is Boston Scientific’s price target?

The average price target for Boston Scientific is 126.05. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $140.00 ,the lowest forecast is $113.00. The average price target represents 26.18% Increase from the current price of $99.9.

What do analysts say about Boston Scientific?

Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of BSX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Boston Scientific (BSX) Stock Forecast & Price Target

BSX Analyst Ratings

BSX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Boston Scientific

BSX Analyst Recommendation Trends

BSX Financial Forecast

BSX Earnings Forecast

BSX Sales Forecast

BSX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts